The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
The lipid-lowering agent pirozadil was tested in 1185 hyperlipidaemic subjects during a 2-4 months' intake. Plasma triglycerides were found to decrease by 30.8%. The reduction of plasma cholesterol (by 20.8%) was mainly due to a fall in low-density lipoprotein cholesterol by 23.7%, while high-density lipoprotein cholesterol increased up to 32.2%. Pirozadil was effective and well-tolerated in patients with both hypercholesterolaemia and hypertriglyceridaemia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*; D013030:Spain; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D011725:Pyridines; D014280:Triglycerides; C015453:pirozadil; D002784:Cholesterol